Tirzepatide Side Effects Explained: SURMOUNT Trial Data, Why They Happen and When They Stop

Tirzepatide has real denominators. SURMOUNT-1 recorded discontinuation for adverse events of 4.3%, 7.1% and 6.2% against 2.6% on placebo across 2,539 participants. It recorded no hair loss rate, and neither did any other trial in the programme.

Those two facts sit oddly together, and holding both is the job of this page. Tirzepatide is the best-evidenced compound in the weight loss and metabolic peptides category, which is exactly why an unmeasured question stands out against it. For per-injection volume there is a tirzepatide calculator, and nothing here is medical advice or a recommendation to use any amount.

What did SURMOUNT-1 count, and what makes those numbers unusual?

SURMOUNT-1 recorded discontinuation due to adverse events of 4.3%, 7.1% and 6.2% at 5, 10 and 15 mg against 2.6% on placebo, across 2,539 participants over 72 weeks. Weight change ran −15.0%, −19.5% and −20.9% against −3.1%, all at P<0.001. Those discontinuation figures are notably low for a class whose dose-limiting problem is gastrointestinal, and the placebo comparator is what makes them interpretable rather than merely reassuring.

The trial is Jastreboff et al., New England Journal of Medicine, July 2022, PMID 35658024, NCT04184622. Read the discontinuation column against the weight-change column and the relationship is not monotonic — the 15 mg arm produced the largest weight loss and a lower discontinuation rate than 10 mg, which is a reminder that tolerability and dose are correlated rather than locked together.

One condition attached to those figures matters more than it usually gets. They were measured on trial material of known content, under a supervised escalation schedule. Both of those conditions are absent from a research-market vial, and the second half of this page is about what happens when the first one fails. The full trial and approval record is in the dual GIP and GLP-1 agonist that beat semaglutide, and the cross-compound context is in peptide side effects.

What does tirzepatide's boxed warning actually say, and what does it rest on?

Tirzepatide carries a boxed warning for thyroid C-cell tumours on both approved products, and that warning rests on rodent findings rather than on a human observation. It should be described as animal data every time it is described at all. Both products are contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2. Mounjaro holds NDA 215866, approved 13 May 2022; Zepbound holds NDA 217806, approved 8 November 2023.

Two label changes have widened who those warnings apply to. Zepbound added moderate to severe obstructive sleep apnoea in adults with obesity via supplement SUPPL-13, approved 20 December 2024. Mounjaro's current label covers "adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus," following SUPPL-39 approved 19 December 2025 — so any description of the labelled adverse-effect profile as adults-only is out of date.

What the label does not carry is worth stating too. There is no heart failure, HFpEF or cardiovascular outcome indication on either product, and tirzepatide does not appear anywhere on the WADA 2026 Prohibited List. As an approved drug it also falls outside WADA's S0 catch-all, which applies to substances with no regulatory approval for human therapeutic use.

Is there a trial-reported hair loss rate for tirzepatide?

No trial-reported alopecia rate for tirzepatide exists in the record this platform holds. SURMOUNT-1, SURMOUNT-5, SURMOUNT-OSA and SURPASS-2 published discontinuation, weight-change and endpoint data across thousands of participants, and neither their adverse-effect reporting nor either approved label supplies a hair loss incidence. That is an absence of a measurement rather than evidence that shedding does not happen, and no number should be quoted for it in either direction, including a reassuringly low one.

The gap is legible precisely because everything around it was counted. This is a compound with published confidence intervals on weight change, a placebo-controlled discontinuation rate at three doses, an apnoea-hypopnoea index reduction of 25.3 events per hour against 5.3 on placebo, and a boxed warning traced to a specific animal finding. Against that background, an unmeasured dermatological question is conspicuous rather than routine.

Anyone quoting a percentage for tirzepatide hair loss is therefore quoting something that came from outside the trial programme. That does not make the experience people are reporting unreal. It makes the number unsourced, which is a different problem and one worth separating from the first.

What is the likely mechanism people are describing when they report shedding?

The most plausible explanation is not a tirzepatide effect at all but a rapid weight loss effect. Telogen effluvium is the general dermatological term for diffuse shedding that follows a physiological stressor, characteristically after a delay of some weeks. This is offered as a mechanism hypothesis and nothing more — no trial in the tirzepatide programme tested it, no incidence exists, and no citation in this corpus attaches it to this drug. The distinction between a mechanism that is plausible and a finding that was measured is the whole point.

There is a corpus precedent for a rapid-weight-loss-mediated effect rather than a receptor-mediated one, and it is instructive. Gallbladder disorders are associated with rapid weight loss generally rather than being specific to any incretin agonist, and STEP 1 recorded them in 2.6% of semaglutide participants against 1.2% on placebo. That is what it looks like when someone actually counts a weight-loss-mediated effect: a modest excess over placebo, published, with a denominator.

If the mechanism really is the weight loss rather than the molecule, several things follow that a drug-attributed framing obscures. It would be expected across any intervention producing loss at a similar rate, including the ones with no pharmacology at all. It would be delayed relative to starting treatment rather than tracking dose. And it would not be predicted to differ much between compounds in this class. All of that is reasoning, not data, and it should be held loosely until somebody collects a dermatological endpoint prospectively. The compound-level record for the class sibling is in semaglutide and the 44.2% nausea rate.

What can honestly be said about managing it?

Very little, and pretending otherwise would be the failure mode here. No peptide covered on this platform has human evidence for preventing or reversing hair shedding, and no tirzepatide-specific management study exists because no tirzepatide-specific incidence study exists either. The follicle literature that gets cited for this purpose is excised follicle culture, which is a screening model rather than a clinical test. A clinician is the right route, because diffuse shedding has many causes worth excluding.

Why the follicle data cannot carry the weight put on it is specific rather than a general shrug. Excised follicle culture removes blood supply, systemic hormones, immune surveillance, sebaceous function and the androgen signalling that drives pattern hair loss in the first place. And the picomolar to nanomolar concentrations used in culture medium bear no defined relationship to what a topical or injected preparation delivers to a dermal papilla, because no human pharmacokinetic study of those compounds exists. A compound that maintains follicles in a dish has passed a screening step, not a clinical one. That assessment is set out in peptides and hair growth research and AHK-Cu and the excised follicle model.

What a clinician can do that a website cannot is exclude the other causes. Diffuse shedding accompanies thyroid disease, iron deficiency, other nutritional deficits, several medications, recent illness and other physiological stressors, and distinguishing between them requires history, examination and bloods rather than a protocol. Anyone losing hair while losing weight rapidly on an approved drug is describing something their prescriber should hear about, not something a peptide article should attempt to treat. No protocol appears on this page, because there is no evidence base to build one from.

How does tirzepatide's tolerability compare with semaglutide's?

Tirzepatide and semaglutide have been compared head-to-head on efficacy and not on a single tolerability endpoint. SURMOUNT-5 randomised 751 adults for 72 weeks and produced −20.2% against −13.7%, a 6.5 percentage point difference at P<0.001. On adverse effects the comparison is cross-trial: tirzepatide's discontinuation ran 4.3% to 7.1% against 2.6% in SURMOUNT-1, while semaglutide's STEP 1 recorded nausea in 44.2% against 17.4% and gastrointestinal discontinuation of 4.5%.

Several cells in that table say "not carried here" rather than giving a number, and that is deliberate: the tirzepatide figures in this corpus are discontinuation figures, and filling the symptom rows with semaglutide's percentages would be exactly the substitution this page exists to refuse. Semaglutide's nausea also has a shape worth knowing — it clusters during dose escalation and fades with continued dosing, which is how a 44.2% incidence coexists with a 4.5% discontinuation rate. That shape is mapped onto a syringe in the semaglutide dosing chart, and the head-to-head in full is in comparing semaglutide and tirzepatide.

Does fill quantity change which side effects you get?

Fill quantity changes the dose without changing anything a person can see. Across 930 independent lab tests on this platform, tirzepatide vial contents run +2.6% to +26.7% over label, with vials labelled 10 to 65 mg testing between 10.71 and 68.1 mg. The approved label titrates in 2.5 mg steps, so the recorded error can exceed the increment — and the error runs toward the gastrointestinal effects that are dose-related and that people discontinue for.

Worked example — a 26.7% overage propagating through the arithmetic

That is arithmetic on a measured variance range, labelled as an example rather than as a recommendation. Its consequence is behavioural rather than pharmacological: a person who believes they are holding at 10 mg is receiving 12.67 mg, past the next rung on the ladder, and the nausea that follows looks exactly like ordinary dose-related nausea rather than like a measurement problem. Attributing it to the step you think you are on is the wrong diagnosis of the right symptom.

The correction requires a number to correct with, which means quantitative content testing on the specific batch — a 30 mg vial assaying 38.01 mg needs 3.8 mL of diluent rather than 3 mL to return to 10 mg/mL. Without a batch assay there is no correction, because a range of +2.6% to +26.7% is too wide to split. The reverse calculator runs that division, the ladder arithmetic is in tirzepatide dosing and reconstitution, and why purity cannot answer a quantity question is in why 10 mg isn't 10 mg.

What has FDA recorded about compounded tirzepatide?

FDA had received more than 215 adverse event reports for compounded tirzepatide as of 30 November 2024, alongside more than 392 for compounded semaglutide, and those figures have not been updated since. They are spontaneous reports rather than trial data, which means they have no denominator and cannot yield an incidence. The agency separately reported "multiple reports of adverse events... that may be related to dosing errors associated with compounded injectable semaglutide products."

Two further FDA positions bear directly on what is in a non-pharmacy vial. On salt forms: "These salt forms... are different active ingredients than are used in the approved drugs. The agency does not have information on whether these salts have the same chemical and pharmacologic properties." On labelling: FDA "has warned companies that have illegally sold unapproved drugs... falsely labeled 'for research purposes' or 'not for human consumption.' These products have been sold directly to consumers for human use."

The route those reports came through has since closed. Compounding an essential copy of an approved drug is permitted only during a shortage, and FDA's shortage database now lists Tirzepatide Injection as Resolved. As the peer-reviewed summary puts it, compounding pharmacies "can only legally sell unique products." Tirzepatide appears on neither of FDA's bulk substances tables, and that absence is not permission. The sequence is in the FDA peptide regulation timeline and compounding pharmacy versus research peptide.

Which tirzepatide side-effect claims survive the evidence?

Four of the ten claims most commonly made about tirzepatide's side effects hold up, and six do not. The discontinuation figures, the boxed warning, the class gastrointestinal burden and the fill-variance risk are all supported by named sources. The failures cluster around numbers nobody published: a hair loss rate, a human basis for the thyroid warning, a claim of no serious warnings at all, and the idea that a 99.75% purity average says something about safety.

What do 930 independent lab tests and the price data show?

The Purity Index records tirzepatide at 99.75% average purity across 930 independent tests (verified August 2026) from Freedom Diagnostics, Kovera, ILS, Accumark and MZ Biolabs, across 227 shops selling — one of the deepest datasets on this platform. Identity is not the failure mode on this compound. Quantity is: variance runs +2.6% to +26.7%, with vials labelled 10 to 65 mg testing between 10.71 and 68.1 mg. A purity figure is a statement about proportion and says nothing about mass.

Tirzepatide price data shows 14 shops in stock, median $5.67/mg, lowest $1.17/mg on a 60 mg vial (verified 9 August 2026), across 48 compared offers with vial prices from $19.99 to $465.00. By vial size, 5-10 mg runs a median $9.60/mg, 15-35 mg $5.69/mg and 40-120 mg $3.85/mg. Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing.

Peptigrity's platform tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026), and trust scores weight community reviews and independently verified HPLC purity equally at 50% each. One consequence of the fill variance is worth carrying into the price figures: a per-milligram price computed from a label that overstates or understates the contents is partly fictional, which is why the cost-per-dose calculator is only as good as the assay behind it. Vendor detail sits on the tirzepatide compound page.

How do you check a vial before attributing a symptom to the drug?

Six checks separate a drug effect from a dose effect, and the two that matter most on this compound are mass and quantity rather than purity. Mass spectrometry against 4,813.0 Da with the C20 diacid attached confirms identity; quantitative content testing on the batch confirms how much is there. A high HPLC figure answers neither question, and on a compound whose recorded variance reaches +26.7% against a 2.5 mg titration step, quantity is the variable most likely to explain a new symptom.

Two things no check on the vial can settle. It cannot tell you whether a symptom is the drug, the dose or something unrelated — that is a clinician's judgment with your history in front of them. And it cannot supply an alopecia rate, because no trial produced one. Sourcing procedure is in where to buy tirzepatide, and reading an endotoxin result is covered in peptide endotoxin testing and LAL interpretation.

The trial that would settle this

Tirzepatide is unusual in that most of its important trials have been run. SURMOUNT-5 settled the semaglutide comparison in 751 patients, SURMOUNT-1 settled obesity efficacy in 2,539, and SURMOUNT-OSA produced an approved indication. What remains open on the adverse-effect side is narrower and more specific: a prospectively collected dermatological endpoint, a market audit of net content against label, and durability past 72 weeks.

Frequently Asked Questions

Does tirzepatide cause hair loss?

No trial in the tirzepatide programme published an alopecia or hair loss incidence, and neither approved label carries one. That means any percentage in circulation came from outside the evidence base. It also means the question is genuinely unanswered rather than answered in the negative, and people reporting shedding are describing something no study set out to count.

What is tirzepatide's discontinuation rate?

In SURMOUNT-1, discontinuation due to adverse events ran 4.3% at 5 mg, 7.1% at 10 mg and 6.2% at 15 mg, against 2.6% on placebo, across 2,539 participants over 72 weeks. Those figures are low for this class, and they were measured on trial material of known content under a supervised escalation schedule.

Is the boxed warning based on human data?

No. The boxed warning for thyroid C-cell tumours on both Mounjaro and Zepbound rests on rodent findings, and should be described as animal data rather than a human observation. Both products are contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2, which is a precaution rather than a recorded human incidence.

How does it compare with semaglutide on nausea?

The two have been compared head-to-head on weight loss, not on tolerability. Semaglutide's STEP 1 recorded nausea in 44.2% against 17.4% on placebo with 4.5% discontinuing for gastrointestinal reasons; tirzepatide's SURMOUNT-1 recorded discontinuation of 4.3% to 7.1% against 2.6%. Those are different endpoints from different trials and populations.

Can an overfilled vial cause side effects?

It can change the dose, and in this class the dose drives the gastrointestinal effects. Recorded fill variance on this platform runs +2.6% to +26.7% against label on a drug titrated in 2.5 mg steps, so at the top of that range an intended 10 mg delivers 12.67 mg. Nothing about the powder or the solution reveals it.

When should someone see a doctor?

Any new or worsening symptom on a prescription drug belongs with the prescriber, and some warrant urgency: severe persistent abdominal pain needs pancreatitis excluded, and diffuse hair shedding has causes including thyroid disease and iron deficiency that are worth excluding with bloods. Nothing on this page is medical advice, and dose changes are a prescriber's decision.

Where this leaves tirzepatide tolerability

Tirzepatide is the compound on this platform where the counting was done properly. Discontinuation of 4.3%, 7.1% and 6.2% against 2.6% on placebo, in 2,539 participants over 72 weeks, is a denominator-backed tolerability record and an unusually good one for its class. The boxed warning is real and rests on rodent thyroid C-cell tumours. Both facts are traceable to named trials and published labels.

Against that, the hair loss question has no number at all — not a high one, not a low one, none. The mechanism people are most likely describing is shedding after rapid weight loss rather than a receptor effect, and that remains a hypothesis nobody has tested in this drug. Inventing an incidence to fill the gap would be the one thing guaranteed to make the page less useful than the trials it reports.

The variable most likely to change what someone actually experiences is not in the trial record at all. Fill quantity on this platform runs +2.6% to +26.7% against a label that titrates in 2.5 mg steps, which means the error can exceed the increment and move a person up a ladder they believe they are holding steady on. The symptom that follows gets blamed on the molecule. The right question is how much of it was in the vial.

Browse the weight loss and metabolic peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume, use the tirzepatide calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.